As a leading global provider for industries operating in high temperature conditions, Calderys continuously strives to ...

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaApproval based on ...

Pomalidomide is under clinical development by Qilu Pharmaceutical and currently in Phase III for Refractory Multiple Myeloma.

Gensci-059 is under clinical development by Changchun GeneScience Pharmaceutical and currently in Phase I for Refractory Acute Myeloid Leukemia.

The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients ...

During a Case-Based Roundtable® event, Jean A. Yared, MD, moderated a discussion on the approach to CAR T-cell therapy for a ...

During a Case-Based Roundtable® event, Rahul Banerjee, MD, discussed approaches to dosing and tolerability when using ...

Geron Corporation's RYTELO gains FDA approval for Low-Risk MDS, with strong sales projections and promising Phase 3 study.

Galapagos NV (NASDAQ:GLPG – Get Free Report) has received an average recommendation of “Reduce” from the eight research firms ...

Y-mAbs Therapeutics announced a strategic business realignment to enhance operational flexibility and accelerate clinical development. The company will establish two business units focusing on ...